Cancer Therapy

2C4 disrupts HER kinase signaling pathway, inhibits ovarian carcinoma cell growth

Published in Cancer Weekly, February 14th, 2006

2C4, a monoclonal antibody against HER2, appears to disrupt the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.

"Human epidermal growth factor receptor 2 (HER2) is overexpressed in 25%-30% of ovarian carcinoma cases and a correlation between increased HER2 expression and decreased survival has been demonstrated. HER2 is a ligand-less 3 member of the HER family that functions as the preferred coreceptor for epidermal 3 growth factor receptor (EGFR), HER3, and HER4," researchers in the United States reported.

"An approach was developed to target HER2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-02-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry